Enfortumab vedotin monotherapy or its combination with pembrolizumab could significantly evolve the treatment landscape for urothelial cancer November, 2022
An epigenetics drug currently being used for the treatment of blood cancers and rare sarcomas can stop the growth of bladder cancer by activating the immune system, reports a new Northwestern Medicine study done in mice and published in Science Advances. October, 2022
Chemoresection Reduces Need for Surgery in Nonmuscle Invasive Bladder Cancer
Toxicity data reveal no safety concerns with S/N1806 bladder cancer trial
An Influx of Data Expands Options, Improves Treatment for Bladder Cancer
Bladder cancer is a type of abnormal cell malignancy that begins in the cells of the bladder, the balloon-shaped organ which functions as a waste storage system for urine.
Transitional cell (urothelial) carcinoma: is cancer that begins in the urinary tract transitional epithelium cells lining the inside of the bladder. Transitional cell carcinoma is the most common kind of bladder cancer, occurring in about 95% of cases.
Squamous cell carcinoma: is cancer that begins when epithelial cells change to squamous cells (thin, flat cells) as a result of chronic irritation and inflammation. About 1% to 2% of bladder cancers are squamous cell carcinomas.
Adenocarcinoma: is cancer that begins in the cells of glandular structures lining the inner lining of the bladder. Adenocarcinomas account for only about 1% of bladder cancers.
Treatments for bladder cancer include surgery, radiation therapy, chemotherapy, and immunotherapy.
Surgery: One of the following surgery options may be performed in the treatment of bladder cancer:
Radiation Therapy: traditional external radiation therapy or internal radiation therapy (seeds, wires, catheters) may be used depending on the type and stage of the cancer.
Chemotherapy: Chemotherapy is often used in combination with other bladder cancer treatments. Chemotherapy is often given either before surgery (neoadjuvant chemo) or after surgery (adjuvant chemo) to lower the chance the cancer will reoccur. Some of the drugs currently approved for bladder cancer include: Adriamycin PFS, Adriamycin RDF, Mitomycin C, Thiotepa, Cisplatin, Doxorubicin Hydrochloride, Platinol, Platinol-AQ
Immunotherapy, or biologic therapy: is a treatment that uses the patient’s immune system to stop the cancer growth. One effective immunotherapy treatment used in the treatment of bladder cancer, BCG (bacillus Calmette-Guerin), is a live but weakened vaccine strain of bovine tuberculosis.
National Cancer Institute clinical trials
Bladder Cancer Advocacy Network Clinical Trials
Swog Cancer Research
Cancer.net clinical trials resource
Bladder Cancer Educational Resources from Cancer.net
Bladder Cancer Webcafe: Online information and support for people with bladder cancer; discussion forum, tips for the newly diagnosed, survival guide for hospitalizations for patients and caregivers.
TARIS® Initiates Dosing of TAR-200 (GemRIS™) in Muscle-Invasive Bladder Cancer Patients Unfit for Curative Intent Therapy
March 14, 2018
Scientists pinpoint bladder cancer patients who could benefit from ‘tumor-softening’ treatment
Cancer Research UK
July 30, 2014
Study: Robotic surgery no better than traditional surgery for bladder cancer
July 23, 2014
Neoadjuvant chemotherapy beneficial in muscle-invasive bladder cancer
Clinical Oncology News
Research Points to new therapies for bladder cancer
American Bladder Cancer Society
American Cancer Society
Bladder Cancer Advocacy Network
Inspire Support Groups
Imerman Angels (to connect directly with another survivor or caregiver through an organization that creates personal, one-on-one connections among patients, survivors, and caregivers)
Fighting Chance- free counseling service for cancer patients and caregivers